Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when SNTI files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsSenti closes $10M convertible debt deal, discloses potential $60M Celadon merger
Filed May 26, 2026 · Period ending May 20, 2026 · ~1 min read
Key Changes
-
high
Senti's subsidiary issued $10 million in senior secured convertible notes to Celadon Partners on May 20, 2026. These notes can convert to equity, potentially diluting existing shareholders, and have priority claim on company assets.
Item 1.01 verify on EDGAR → -
high
Company disclosed potential merger with Celadon affiliate that would give shareholders contingent value rights worth up to $60 million total, payable only if drug candidate SENTI-202 hits regulatory and sales milestones.
Item 9.01 verify on EDGAR → -
high
Proposed transactions require shareholder vote. Company will file proxy materials with SEC and hold special meeting for approval of additional convertible note issuances and potential Celadon merger.
Item 9.01 verify on EDGAR → -
medium
Directors and executive officers entered voting agreements with Celadon in connection with the financing. Company and subsidiaries guaranteed the notes and granted registration rights to the lender.
Item 1.01 verify on EDGAR →
Summary
Senti Biosciences completed a $10 million convertible debt financing with Celadon Partners on May 20, marking the close of a deal announced in April. The notes are senior secured, meaning Celadon has first claim on company assets and can convert the debt to equity shares.
More significantly, the 8-K reveals Senti is contemplating a merger with a Celadon-affiliated entity that would fundamentally change the company's ownership structure. Under the proposed merger, current shareholders would receive contingent value rights potentially worth up to $60 million in aggregate—but only if the company's lead drug candidate, SENTI-202, achieves specific regulatory approvals and sales targets.
This structure shifts shareholder value from current equity to milestone-dependent payouts. Both the convertible notes and merger require shareholder approval at an upcoming special meeting. Retail investors should watch for the proxy filing, which will detail conversion terms, voting control implications, and the specific SENTI-202 milestones that trigger the $60 million payout. The involvement of directors and officers in voting agreements with Celadon suggests management supports the transaction, but shareholders will need to assess whether the contingent rights adequately compensate for potential dilution and change of control.
Section-by-Section Diff
Event · Item 1.01 — Entry into a Material Definitive Agreement
Item 1.01 — Entry into a Material Definitive Agreement filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
On May 20, 2026, Senti Holdings, Inc. (“Senti Holdings”), a wholly owned subsidiary of Senti Biosciences Holdings, Inc. (the “Company”), issued and sold to Celadon Partners SPV 24 (“Celadon”) $10.0 million in aggregate principal amount of its Senior Secured Convertible Notes (the “Notes”) pursuant to the previously announced Securities Purchase Agreement, dated April 27, 2026, by and among the Company, Senti Holdings, Senti Biosciences Inc. and Celadon.
The company's subsidiary completed a $10 million convertible debt financing with Celadon Partners. This follows a previously announced securities purchase agreement from April 2026. The notes are senior secured, meaning they have priority claim on company assets and can convert to equity.
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
In connection with the issuance and sale of the Notes on May 20, 2026, Acquiom Agency Services LLC was appointed collateral agent for the Notes
Acquiom Agency Services was appointed as collateral agent to manage the security interests backing the notes. This is a standard administrative role in secured debt transactions to protect lender interests.
Event · Item 2.03 — Creation of a Direct Financial Obligation
8-K discloses creation of a direct financial obligation, with details incorporated by reference from Item 1.01 (not provided in excerpt).
Added in current filing · verify on EDGAR →
Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information contained above in Item 1.01 of this Current Report on Form 8-K is hereby incorporated by reference into this Item 2.03.
The company disclosed the creation of a direct financial obligation or off-balance sheet arrangement under Item 2.03. The specific terms, amounts, and nature of this obligation are referenced in Item 1.01 of the same 8-K filing, which was not included in the provided excerpt. Investors should review Item 1.01 for material details about this new financial commitment.
Event · Item 9.01 — Financial Statements and Exhibits
Item 9.01 — Financial Statements and Exhibits filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
Form of Senior Secured Convertible Note of Senti Holdings, Inc.
The company has issued or is issuing senior secured convertible notes. These are debt instruments that can convert to equity, secured by company assets, which may dilute existing shareholders upon conversion and create priority claims on assets.
Added in current filing · verify on EDGAR →
the potential transaction pursuant to which, if consummated, an entity affiliated with Celadon would merge with and into Senti Holdings and Senti Holdings would issue a contingent value right to the Company’s stockholders, which may pay out up to an aggregate of $60.0 million in cash subject to the achievement of certain regulatory and sales milestones with respect to the Company’s product candidate, SENTI-202
Senti is contemplating a merger with a Celadon-affiliated entity. If completed, shareholders would receive contingent value rights potentially worth up to $60 million total, payable only if SENTI-202 achieves specific regulatory approvals and sales targets. This represents a potential change of control and future value dependent on product success.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · May 27, 2026 · How we verify